GlassScriptPhysician profile
Mark Shukhman
NPI 1225087752
$249,921.38
in general payments reported to CMS, 2019-2025
45 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $16K · 2021: $28K · 2022: $35K · 2023: $60K · 2024: $68K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Travel and Lodging: $11K · Food and Beverage: $11K · Consulting Fee: $7,300 · Honoraria: $2,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,617.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,448.02 |
| Travel and Lodging | $11,315.53 |
| Food and Beverage | $11,236.69 |
| Consulting Fee | $7,300.00 |
| Honoraria | $2,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $61,735.45 | 2021-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Abbvie INC. | $58,479.16 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $29,036.81 | 2019-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27,548.99 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $26,014.73 | 2022-2024 | Quviviq |
| Noven Pharmaceuticals, INC. | $13,182.06 | 2023-2024 | Xelstrym |
| Allergan, INC. | $12,931.13 | 2019-2020 | |
| Mdd US Operations, LLC | $4,761.42 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $2,457.12 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Noven Therapeutics, LLC | $2,166.67 | 2023-2025 | Xelstrym |
| Neurocrine Biosciences, INC. | $1,411.16 | 2019-2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $1,092.47 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $947.49 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Jazz Pharmaceuticals INC. | $923.95 | 2021-2025 | |
| Neos Therapeutics, LP | $922.79 | 2019-2025 | Adzenys Xr-Odt |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $913.50 | 2019-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $631.25 | 2019-2025 | Invega Sustenna |
| Corium, LLC | $557.30 | 2021-2024 | Azstarys, Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $403.21 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $387.24 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $373.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $353.53 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $330.93 | 2022-2024 | Auvelity, Sunosi |
| Lundbeck LLC | $326.17 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $308.11 | 2019 | |
| Neuronetics, INC. | $278.76 | 2019-2021 | |
| Sage Therapeutics, LLC | $238.20 | 2022-2023 | |
| Abbott Laboratories | $155.12 | 2022 | |
| Shire North American Group INC | $148.72 | 2019 | |
| Medtronic, INC. | $116.54 | 2021 | |
| Pfizer INC. | $109.97 | 2020-2023 | |
| Biogen, INC. | $101.03 | 2024 | |
| Eisai INC. | $97.89 | 2021 | |
| Owp Pharmaceuticals, INC. | $87.91 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $54.03 | 2019-2020 | |
| Bausch Health US, LLC | $46.91 | 2019-2020 | |
| Livanova USA, INC. | $45.37 | 2019-2023 | Vns Therapy Symmetry Model 8103 Generator |
| Almatica Pharma LLC | $43.73 | 2023 | Loreev Xr |
| Harmony Biosciences LLC | $42.49 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $42.42 | 2020-2023 | Nuplazid |
| Uswm, LLC | $38.20 | 2023 | Lucemyra, Zimhi |
| Orexo US, INC. | $34.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.31 | 2020 | |
| Adlon Therapeutics L.P. | $14.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shukhman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.